Literature DB >> 33371469

Microphthalmia-Associated Transcription Factor-Dependent Melanoma Cell Adhesion Molecule Activation Promotes Peritoneal Metastasis of Ovarian Cancer.

Kazuhisa Kitami1, Masato Yoshihara1, Yoshihiro Koya2, Mai Sugiyama2, Shohei Iyoshi1,3, Kaname Uno1,4, Kazumasa Mogi1, Sho Tano1, Hiroki Fujimoto1, Akihiro Nawa2, Fumitaka Kikkawa1, Hiroaki Kajiyama1.   

Abstract

Ovarian cancer (OvCa) is one of the leading causes of death due to its high metastasis rate to the peritoneum. Recurrent peritoneal tumors also develop despite the use of conventional platinum-based chemotherapies. Therefore, it is still important to explore the factors associated with peritoneal metastasis, as these predict the prognosis of patients with OvCa. In this study, we investigated the function of microphthalmia-associated transcription factor (MITF), which contributes to the development of melanoma, in epithelial ovarian cancer (OvCa). High MITF expression was significantly associated with a poor prognosis in OvCa. Notably, MITF contributed to the motility and invasion of OvCa cells, and specifically with their peri-mesothelial migration. In addition, MITF-positive cells expressed the melanoma cell adhesion molecule (MCAM/CD146), which was initially identified as a marker of melanoma progression and metastasis, and MCAM expression was regulated by MITF. MCAM was also identified as a significant prognostic factor for poor progression-free survival in patients with OvCa. Collectively, our results suggest that MITF is a novel therapeutic target that potentially promotes peritoneal metastasis of OvCa.

Entities:  

Keywords:  CD146; EMT; MCAM; MITF; invasion; mesothelial; metastasis; migration; ovarian cancer

Mesh:

Substances:

Year:  2020        PMID: 33371469      PMCID: PMC7767511          DOI: 10.3390/ijms21249776

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  59 in total

1.  Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).

Authors:  Djamel Aggoune; Nathalie Sorel; Marie-Laure Bonnet; Jean-Michel Goujon; Karin Tarte; Olivier Hérault; Jorge Domenech; Delphine Réa; Laurence Legros; Hyacinthe Johnson-Ansa; Philippe Rousselot; Emilie Cayssials; Agnès Guerci-Bresler; Annelise Bennaceur-Griscelli; Jean-Claude Chomel; Ali G Turhan
Journal:  Leuk Res       Date:  2017-07-26       Impact factor: 3.156

2.  M-CAM expression as marker of poor prognosis in epithelial ovarian cancer.

Authors:  Daniela Aldovini; Francesca Demichelis; Claudio Doglioni; Dolores Di Vizio; Enzo Galligioni; Sonia Brugnara; Bruna Zeni; Claudia Griso; Cristina Pegoraro; Marina Zannoni; Manuela Gariboldi; Emanuela Balladore; Delia Mezzanzanica; Silvana Canevari; Mattia Barbareschi
Journal:  Int J Cancer       Date:  2006-10-15       Impact factor: 7.396

3.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

Authors:  Levi A Garraway; Hans R Widlund; Mark A Rubin; Gad Getz; Aaron J Berger; Sridhar Ramaswamy; Rameen Beroukhim; Danny A Milner; Scott R Granter; Jinyan Du; Charles Lee; Stephan N Wagner; Cheng Li; Todd R Golub; David L Rimm; Matthew L Meyerson; David E Fisher; William R Sellers
Journal:  Nature       Date:  2005-07-07       Impact factor: 49.962

4.  Ovarian cancer statistics, 2018.

Authors:  Lindsey A Torre; Britton Trabert; Carol E DeSantis; Kimberly D Miller; Goli Samimi; Carolyn D Runowicz; Mia M Gaudet; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2018-05-29       Impact factor: 508.702

5.  Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.

Authors:  Ian J Davis; Jessica J Kim; Fatih Ozsolak; Hans R Widlund; Orit Rozenblatt-Rosen; Scott R Granter; Jinyan Du; Jonathan A Fletcher; Christopher T Denny; Stephen L Lessnick; W Marston Linehan; Andrew L Kung; David E Fisher
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

6.  c-Met expression is regulated by Mitf in the melanocyte lineage.

Authors:  Gaël G McGill; Rizwan Haq; Emi K Nishimura; David E Fisher
Journal:  J Biol Chem       Date:  2006-02-02       Impact factor: 5.157

Review 7.  Treatment of recurrent epithelial ovarian cancer.

Authors:  Sandro Pignata; Carmela Pisano; Marilena Di Napoli; Sabrina Chiara Cecere; Rosa Tambaro; Laura Attademo
Journal:  Cancer       Date:  2019-12-15       Impact factor: 6.860

8.  Cloning of MITF, the human homolog of the mouse microphthalmia gene and assignment to chromosome 3p14.1-p12.3.

Authors:  M Tachibana; L A Perez-Jurado; A Nakayama; C A Hodgkinson; X Li; M Schneider; T Miki; J Fex; U Francke; H Arnheiter
Journal:  Hum Mol Genet       Date:  1994-04       Impact factor: 6.150

9.  Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells.

Authors:  Guo-Fang Zeng; Shao-Xi Cai; Guang-Jer Wu
Journal:  BMC Cancer       Date:  2011-03-30       Impact factor: 4.430

10.  MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61.

Authors:  Mahsa Zarei; Krinio Giannikou; Heng Du; Heng-Jia Liu; Melissa Duarte; Sneha Johnson; Amin H Nassar; Hans R Widlund; Elizabeth P Henske; Henry W Long; David J Kwiatkowski
Journal:  Oncogene       Date:  2020-10-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.